3-benzyl-2-(1-bromopropyl)furo[2,3-e]pyrimidin-4-one | 1333405-21-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-benzyl-2-(1-bromopropyl)furo[2,3-e]pyrimidin-4-one
• CAS: 1333405-21-2
• 化学式: C₁₆H₁₅BrN₂O₂
• 分子量: 347.211
• InChiKey: FJCMQUAGWKSRAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.88
• 重原子数：
  21.0
• 可旋转键数：
  4.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  48.03
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  3-benzyl-2-(1-bromopropyl)furo[2,3-e]pyrimidin-4-one 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 120.5h， 生成 tert-butyl N-[3-[1-(3-benzyl-4-oxofuro[3,2-d]pyrimidin-2-yl)propyl-(4-methylbenzoyl)amino]propyl]carbamate
  参考文献：
  名称：

  Discovery of (+)-N-(3-Aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a Kinesin Spindle Protein Inhibitor and Potential Anticancer Agent

  摘要：

  Structure activity relationship analysis identified (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), from a series of novel kinesin spindle protein (KSP) inhibitors, as exhibiting both excellent biochemical potency and pharmaceutical properties suitable for clinical development. The selected compound arrested cells in mitosis leading to the formation of the monopolar spindle phenotype characteristic of KSP inhibition and induction of cellular death. A favorable pharmacokinetic profile and notable in vivo efficacy supported the selection of this compound as a clinical candidate for the treatment of cancer.

  DOI：

  10.1021/jm200629m
• 作为产物：
  描述：

  N-furan-3-ylbutanamide 在 盐酸羟胺 、 溴 、 sodium acetate 、 四丁基硫酸氢铵 、 magnesium sulfate 、 potassium carbonate 、 对甲苯磺酸 、 potassium hydroxide 、 三氯氧磷 作用下， 以 溶剂黄146 、 甲苯 、 叔丁醇 为溶剂， 反应 24.75h， 生成 3-benzyl-2-(1-bromopropyl)furo[2,3-e]pyrimidin-4-one
  参考文献：
  名称：

  Discovery of (+)-N-(3-Aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a Kinesin Spindle Protein Inhibitor and Potential Anticancer Agent

  摘要：

  Structure activity relationship analysis identified (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), from a series of novel kinesin spindle protein (KSP) inhibitors, as exhibiting both excellent biochemical potency and pharmaceutical properties suitable for clinical development. The selected compound arrested cells in mitosis leading to the formation of the monopolar spindle phenotype characteristic of KSP inhibition and induction of cellular death. A favorable pharmacokinetic profile and notable in vivo efficacy supported the selection of this compound as a clinical candidate for the treatment of cancer.

  DOI：

  10.1021/jm200629m